Equity Profile

INSM

Insmed Incorporated

Health CareBiotechnology$20.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious and rare diseases. Operating in the health care sector, Insmed's work is crucial as it addresses unmet medical needs, particularly in the field of rare diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and its ability to scale its operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

In Q1 2026, Insmed reported an EPS of -$0.76, which was better than the expected -$0.90, resulting in a 15.84% surprise. However, the stock price fell by 23.41% the following day, indicating market disappointment despite the better-than-expected EPS.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Insmed's upcoming earnings report, hoping for signs of revenue growth and advancements in its drug pipeline. However, the company's history of missing estimates raises concerns about its ability to meet expectations this quarter.

Bull Case

If Insmed can demonstrate significant progress in its drug pipeline and report better-than-expected revenue, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company fails to show meaningful revenue growth or progress in its pipeline, it may face further stock price declines, especially given its recent history of disappointing earnings.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Insmed's drug pipeline and when can we expect new data?

Updates on the pipeline can significantly affect investor sentiment and expectations for future revenue.

How does Insmed plan to improve revenue growth in the upcoming quarters?

Understanding the company's strategy for revenue growth will be critical for assessing its financial health and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Insmed's pipeline to deliver unexpected results, particularly given recent advancements in rare disease treatments.

Supporting Evidence

Insmed's recent EPS surprise indicates potential for better-than-expected performance.

The options market is pricing in a significant move, suggesting traders anticipate volatility that could favor a positive outcome.

Key Risk

If the drug pipeline shows unexpected progress, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around Insmed's ability to translate its pipeline developments into tangible revenue growth.

Bull Confirmed If

Demonstrating a clear path to revenue growth with a strong pipeline update could confirm the bull case.

Bear Confirmed If

Failure to provide any positive updates on revenue or pipeline progress would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.5M

10,699 sh

1 insider

Net

$1.5M

Net selling

Most Active Insiders· 4 open-market trades

Chair and CEOLewis William
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations and raises guidance, history suggests the stock could see an average one-day move of +16.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around -1.76%, indicating continued market skepticism.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and progress of key drugs in the pipeline.
2Any commentary on strategies to enhance revenue growth.
3Insights into market demand for Insmed's therapies.
4Management's outlook on competitive positioning within the biotechnology sector.
5Details on partnerships or collaborations that could impact future growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and its ability to scale its operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

INSM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-22.08%

Avg Stock Reaction

-1.20%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Insmed can demonstrate significant progress in its drug pipeline and report better-than-expected revenue, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Insmed's drug pipeline and when can we expect new data?

Updates on the pipeline can significantly affect investor sentiment and expectations for future revenue.

How does Insmed plan to improve revenue growth in the upcoming quarters?

Understanding the company's strategy for revenue growth will be critical for assessing its financial health and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Insmed's pipeline to deliver unexpected results, particularly given recent advancements in rare disease treatments.

Supporting Evidence

Insmed's recent EPS surprise indicates potential for better-than-expected performance.

The options market is pricing in a significant move, suggesting traders anticipate volatility that could favor a positive outcome.

Key Risk

If the drug pipeline shows unexpected progress, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around Insmed's ability to translate its pipeline developments into tangible revenue growth.

Bull Confirmed If

Demonstrating a clear path to revenue growth with a strong pipeline update could confirm the bull case.

Bear Confirmed If

Failure to provide any positive updates on revenue or pipeline progress would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.56%

Historical Avg

±7.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±21.6% while INSM has averaged ±7.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

92.2%

Calls (408K)P/C Ratio: 1.13Puts (123K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.5M

10,699 sh

1 insider

Net

$1.5M

Net selling

Most Active Insiders· 4 open-market trades

Chair and CEOLewis William
$1.5M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insmed beats expectations and raises guidance, history suggests the stock could see an average one-day move of +16.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience a muted reaction, reflecting uncertainty.

Miss

If the company misses expectations, history suggests a potential decline of around -1.76%, indicating continued market skepticism.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and progress of key drugs in the pipeline.
2Any commentary on strategies to enhance revenue growth.
3Insights into market demand for Insmed's therapies.
4Management's outlook on competitive positioning within the biotechnology sector.
5Details on partnerships or collaborations that could impact future growth.